Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2011

Open Access 01-12-2011 | Research article

Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study

Authors: Thomas Paparrigopoulos, Elias Tzavellas, Dimitris Karaiskos, Georgia Kourlaba, Ioannis Liappas

Published in: BMC Psychiatry | Issue 1/2011

Login to get access

Abstract

Background

GABAergic anticonvulsants have been recommended for the treatment of alcohol dependence and the prevention of relapse. Several studies have demonstrated topiramate's efficacy in improving drinking behaviour and maintaining abstinence. The objective of the present open-label controlled study was to assess efficacy and tolerability of low-dose topiramate as adjunctive treatment in alcohol dependence during the immediate post-detoxification period and during a 16-week follow-up period after alcohol withdrawal.

Methods

Following a 7-10 day inpatient alcohol detoxification protocol, 90 patients were assigned to receive either topiramate (up to 75 mg per day) in addition to psychotherapeutic treatment (n = 30) or psychotherapy alone (n = 60). Symptoms of depression and anxiety, as well as craving, were monitored for 4-6 weeks immediately following detoxification on an inpatient basis. Thereafter, both groups were followed as outpatients at a weekly basis for another 4 months in order to monitor their course and abstinence from alcohol.

Results

A marked improvement in depressive (p < 0.01), anxiety (p < 0.01), and obsessive-compulsive drinking symptoms (p < 0.01) was observed over the consecutive assessments in both study groups. However, individuals on topiramate fared better than controls (p < 0.01) during inpatient treatment. Moreover, during the 4-month follow up period, relapse rate was lower among patients who received topiramate (66.7%) compared to those who received no adjunctive treatment (85.5%), (p = 0.043). Time to relapse in the topiramate augmentation group was significantly longer compared to the control group (log rank test, p = 0.008). Thus, median duration of abstinence was 4 weeks for the non-medicated group whereas it reached 10 weeks for the topiramate group. No serious side effects of topiramate were recorded throughout the study.

Conclusions

Low-dose topiramate as an adjunct to psychotherapeutic treatment is well tolerated and effective in reducing alcohol craving, as well as symptoms of depression and anxiety, present during the early phase of alcohol withdrawal. Furthermore, topiramate considerably helps to abstain from drinking during the first 16-week post-detoxification period.
Appendix
Available only for authorised users
Literature
1.
Johnson BA, Swift RM, Ait-Daoud N, DiClemente CC, Javors MA, Malcolm RJ: Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. Alcohol Clin Exp Res. 2004, 28 (2): 295-301. 10.1097/01.ALC.0000113409.47937.6C.CrossRefPubMed
2.
3.
Arbaizar B, Diersen-Sotos T, Gomez-Acebo I, Llorca J: Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Esp Psiquiatr. 2010, 38 (1): 8-12.PubMed
4.
Johnson BA, Ait-Daoud N: Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des. 2010, 16 (19): 2103-2112. 10.2174/138161210791516404.CrossRefPubMedPubMedCentral
5.
Deng C, Li KY, Zhou C, Ye JH: Ethanol enhances glutamate transmission by retrograde dopamine signaling in a postsynaptic neuron/synaptic bouton preparation from the ventral tegmental area. Neuropsychopharmacology. 2009, 34 (5): 1233-1244. 10.1038/npp.2008.143.CrossRefPubMed
6.
Xiao C, Shao XM, Olive MF, Griffin WC, Li KY, Krnjevic K, Zhou C, Ye JH: Ethanol facilitates glutamatergic transmission to dopamine neurons in the ventral tegmental area. Neuropsychopharmacology. 2009, 34 (2): 307-318. 10.1038/npp.2008.99.CrossRefPubMed
7.
Heilig M, Egli M: Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006, 111 (3): 855-876. 10.1016/j.pharmthera.2006.02.001.CrossRefPubMed
8.
Johnson BA: Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. Alcohol Clin Exp Res. 2004, 28 (8): 1137-1144. 10.1097/01.ALC.0000134533.96915.08.CrossRefPubMed
9.
Kleber HD, Weiss RD, Anton RF, George TP, Greenfield SF, Kosten TR, O'Brien CP, Rounsaville BJ, Strain EC, Ziedonis DM, et al: Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007, 164 (4 Suppl): 5-123.PubMed
10.
Driessen M, Meier S, Hill A, Wetterling T, Lange W, Junghanns K: The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol Alcohol. 2001, 36 (3): 249-255.CrossRefPubMed
11.
Willinger U, Lenzinger E, Hornik K, Fischer G, Schonbeck G, Aschauer HN, Meszaros K: Anxiety as a predictor of relapse in detoxified alcohol-dependent patients. Alcohol Alcohol. 2002, 37 (6): 609-612.CrossRefPubMed
12.
Liappas J, Paparrigopoulos T, Tzavellas E, Rabavilas A: Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Prog Neuropsychopharmacol Biol Psychiatry. 2005, 29 (1): 55-60. 10.1016/j.pnpbp.2004.10.005.CrossRefPubMed
13.
14.
Chiu YH, Lee TH, Shen WW: Use of low-dose topiramate in substance use disorder and bodyweight control. Psychiatry Clin Neurosci. 2007, 61 (6): 630-633. 10.1111/j.1440-1819.2007.01718.x.CrossRefPubMed
15.
Martinotti G, Di Nicolaa M, De Vitaa O, Tedeschia D, Guerrieroa L, Guglielmoa R, De Filippisa R, Janiri L: Low-dosage topiramate in alcohol dependence: a randomized, double-blind, placebo-controlled trial. European Psychiatry, 18th European Congress of Psychiatry, Poster: 2010. 2010, 1665-
16.
Diagnostic and statistical manual of mental disorders DSM-IV-TR (Revised 4th ed). 2000, Washington, DC: American Psychiatric Association
17.
Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N: SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990, 47 (6): 589-593.CrossRefPubMed
18.
Magura S, Kang SY: Validity of self-reported drug use in high risk populations: a meta-analytical review. Subst Use Misuse. 1996, 31 (9): 1131-1153. 10.3109/10826089609063969.CrossRefPubMed
19.
Salaspuro M: Carbohydrate-deficient transferrin as compared to other markers of alcoholism: a systematic review. Alcohol. 1999, 19 (3): 261-271. 10.1016/S0741-8329(99)00044-0.CrossRefPubMed
20.
Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, et al: The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry. 1988, 45 (12): 1069-1077.CrossRefPubMed
21.
22.
23.
Anton RF, Moak DH, Latham P: The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995, 19 (1): 92-99. 10.1111/j.1530-0277.1995.tb01475.x.CrossRefPubMed
24.
Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976, 33 (6): 766-771.CrossRefPubMed
25.
Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM: Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989, 84 (11): 1353-1357. 10.1111/j.1360-0443.1989.tb00737.x.CrossRefPubMed
26.
Johnson BA, Ait-Daoud N, Roache JD: The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J Stud Alcohol Suppl. 2005, 157-167. discussion 140, 15
27.
Olive MF: Pharmacotherapies for alcoholism: the old and the new. CNS Neurol Disord Drug Targets. 2010, 9 (1): 2-4.CrossRefPubMed
28.
Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ: Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003, 361 (9370): 1677-1685. 10.1016/S0140-6736(03)13370-3.CrossRefPubMed
29.
Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, et al: Topiramate for treating alcohol dependence: a randomized controlled trial. Jama. 2007, 298 (14): 1641-1651. 10.1001/jama.298.14.1641.CrossRefPubMed
30.
Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG: Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction. 2008, 103 (12): 2035-2044. 10.1111/j.1360-0443.2008.02355.x.CrossRefPubMed
31.
De Sousa AA, De Sousa J, Kapoor H: An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat. 2008, 34 (4): 460-463. 10.1016/j.jsat.2007.05.012.CrossRefPubMed
32.
Florez G, Saiz PA, Garcia-Portilla P, Alvarez S, Nogueiras L, Bobes J: Topiramate for the Treatment of Alcohol Dependence: Comparison with Naltrexone. Eur Addict Res. 2010, 17 (1): 29-36. 10.1159/000320471.CrossRefPubMed
33.
Gass JT, Olive MF: Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol. 2008, 75 (1): 218-265. 10.1016/j.bcp.2007.06.039.CrossRefPubMed
34.
Roberto M, Madamba SG, Moore SD, Tallent MK, Siggins GR: Ethanol increases GABAergic transmission at both pre- and postsynaptic sites in rat central amygdala neurons. Proc Natl Acad Sci USA. 2003, 100 (4): 2053-2058. 10.1073/pnas.0437926100.CrossRefPubMedPubMedCentral
35.
36.
Olmsted CL, Kockler DR: Topiramate for alcohol dependence. Ann Pharmacother. 2008, 42 (10): 1475-1480. 10.1345/aph.1L157.CrossRefPubMed
37.
Luykx JJ, Carpay JA: Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders. Expert Opin Drug Saf. 2010, 9 (4): 623-631. 10.1517/14740331003739196.CrossRefPubMed
38.
39.
Charney DA, Zikos E, Gill KJ: Early recovery from alcohol dependence: factors that promote or impede abstinence. J Subst Abuse Treat. 2010, 38 (1): 42-50. 10.1016/j.jsat.2009.06.002.CrossRefPubMed
40.
Dawe S, Loxton NJ: The role of impulsivity in the development of substance use and eating disorders. Neurosci Biobehav Rev. 2004, 28 (3): 343-351. 10.1016/j.neubiorev.2004.03.007.CrossRefPubMed
41.
42.
Prado-Lima PA: [Pharmacological treatment of impulsivity and aggressive behavior]. Rev Bras Psiquiatr. 2009, 31 (Suppl 2): S58-65.PubMed
43.
Leung KS, Cottler LB: Treatment of pathological gambling. Curr Opin Psychiatry. 2009, 22 (1): 69-74. 10.1097/YCO.0b013e32831575d9.CrossRefPubMed
44.
McElroy SL, Guerdjikova AI, Martens B, Keck PE, Pope HG, Hudson JI: Role of antiepileptic drugs in the management of eating disorders. CNS Drugs. 2009, 23 (2): 139-156. 10.2165/00023210-200923020-00004.CrossRefPubMed
45.
Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E: Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2010,
46.
Liappas J, Paparrigopoulos T, Tzavellas E, Christodoulou G: Impact of alcohol detoxification on anxiety and depressive symptoms. Drug Alcohol Depend. 2002, 68 (2): 215-220. 10.1016/S0376-8716(02)00195-3.CrossRefPubMed
47.
Paparrigopoulos T, Tzavellas E, Karaiskos D, Malitas P, Liappas I: An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects. J Psychopharmacol. 2010, 24 (9): 1375-1380. 10.1177/0269881109103799.CrossRefPubMed
48.
Bottlender M, Soyka M: Impact of craving on alcohol relapse during, and 12 months following, outpatient treatment. Alcohol Alcohol. 2004, 39 (4): 357-361.CrossRefPubMed
Metadata
Title
Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study
Authors
Thomas Paparrigopoulos
Elias Tzavellas
Dimitris Karaiskos
Georgia Kourlaba
Ioannis Liappas
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2011
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-11-41

Other articles of this Issue 1/2011

BMC Psychiatry 1/2011 Go to the issue

Research article

A randomized controlled pilot study of a brief web-based mindfulness training

Research article

Physical health behaviours and health locus of control in people with schizophrenia-spectrum disorder and bipolar disorder: a cross-sectional comparative study with people with non-psychotic mental illness

Study protocol

A study of a culturally focused psychiatric consultation service for Asian American and Latino American primary care patients with depression

Research article

Reduced antioxidant defense in early onset first-episode psychosis: a case-control study

Study protocol

ALGOS: the development of a randomized controlled trial testing a case management algorithm designed to reduce suicide risk among suicide attempters

Research article

Substance abuse and psychiatric co-morbidity as predictors of premature mortality in Swedish drug abusers a prospective longitudinal study 1970 - 2006